Violetta Filas

ORCID: 0000-0003-2028-877X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Estrogen and related hormone effects
  • HER2/EGFR in Cancer Research
  • Cutaneous lymphoproliferative disorders research
  • Cancer Diagnosis and Treatment
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Multiple and Secondary Primary Cancers
  • Lymphoma Diagnosis and Treatment
  • Cancer-related Molecular Pathways
  • Cancer Genomics and Diagnostics
  • Cytokine Signaling Pathways and Interactions
  • Dialysis and Renal Disease Management
  • T-cell and Retrovirus Studies
  • BRCA gene mutations in cancer
  • PI3K/AKT/mTOR signaling in cancer
  • FOXO transcription factor regulation
  • Monoclonal and Polyclonal Antibodies Research
  • DNA Repair Mechanisms
  • Sarcoma Diagnosis and Treatment
  • Virus-based gene therapy research
  • Colorectal and Anal Carcinomas
  • Chromatin Remodeling and Cancer
  • Colorectal Cancer Treatments and Studies
  • Advanced Breast Cancer Therapies
  • Genetic factors in colorectal cancer

Poznan University of Medical Sciences
2007-2021

Greater Poland Cancer Center
2011-2021

Centrum Onkologii
1998-2013

University School of Physical Education in Kraków
2000

Cell culture is a widely used in vitro tool for improving our understanding of cell biology, tissue morphology, and mechanisms diseases, drug action, protein production the development engineering. Most research regarding cancer biology based on experiments using two-dimensional (2D) cultures vitro. However, 2D have many limitations, such as disturbance interactions between cellular extracellular environments, changes polarity, method division. These disadvantages led to creation models...

10.5114/aoms.2016.63743 article EN cc-by-nc-sa Archives of Medical Science 2016-01-01

// Patrycja Czerwińska 1, 2, 3 , Parantu K. Shah 4 Katarzyna Tomczak Marta Klimczak Sylwia Mazurek Barbara Sozańska 5 Przemysław Biecek 5, 6 Konstanty Korski 7 Violetta Filas Andrzej Mackiewicz 2 Jannik N. Andersen Maciej Wiznerowicz 1 Laboratory for Gene Therapy, Department of Diagnostics and Cancer Immunology, Greater Poland Centre, Poznan, Chair Medical Biotechnology, Poznan University Sciences, Postgraduate School Molecular Medicine, Warsaw, Institute Applied Science, Texas MD Anderson...

10.18632/oncotarget.13273 article EN Oncotarget 2016-11-10

Diabetes mellitus, as a risk factor for endometrial cancer (EC), causes an increase in insulin and IGF-1 concentrations the blood serum. The are considered mitogenic factors contributory to development. Studies suggest that metformin has preventive activity, decreasing mortality of neoplasms. Since estrogen (ER), progesterone (PR) (IGF-1R) receptor expression β-catenin PAX-2 mutations significant development cancer, it was decided study these patients with type 2 diabetes mellitus (DM2),...

10.1186/1758-5996-5-76 article EN cc-by Diabetology & Metabolic Syndrome 2013-12-01

Interleukin-6 (IL-6) is secreted by normal epithelial breast cells but not oncogene-transformed cells. able to inhibit growth of carcinoma in culture. exerts its activity via two receptor subunits, IL-6R and glycoprotein 130 (gp130). The expression these subunits tumors has been studied, there are no previous reports their prognostic significance, the authors' knowledge.mRNA IL-6, IL-6R, gp130 was studied 75 tumor samples obtained from patients. Patients were followed for a maximum 71 months...

10.1002/(sici)1097-0142(20000501)88:9<2061::aid-cncr12>3.0.co;2-o article EN Cancer 2000-05-01

Breast cancers (BC) in women carrying mutations BRCA1 gene are more frequently estrogen receptor negative than the nonhereditary BC. Nevertheless, tamoxifen has been found to have a protective effect preventing contralateral tumors mutation carriers. The identification of second human receptor, ERbeta, raised question its role hereditary breast cancer. aim this study was assess frequency ERalpha, PgR (progesterone receptor) and HER-2 expression cancer patients with mutated control group.The...

10.1186/1471-2407-8-100 article EN cc-by BMC Cancer 2008-04-13

Her-2/neu is overexpressed in 20-30% of breast cancer patients and associated with a more aggressive disease. Identification Her-2/c-erbB-2-neu overexpression based on immunohistochemical [ihc] detection protein and/or gene amplification fluorescence situ hybridization test (FISH). Also Estrogen receptors [ER] Progesterone [PR] are the prognostic predictive biomarkers, recently analysed by ihc methods. Subjective, manual scoring expression ER/PR reported as percentage immunopositive cells...

10.2478/v10042-010-0015-1 article EN cc-by-nc-nd Folia Histochemica et Cytobiologica 2010-06-08

We present the interesting case of a 38‐year‐old man with primary malignant tumor right testis that metachronously metastasized to urinary bladder and stomach. Histologically, testicular was mixed germ cell composed teratoma embryonal carcinoma, but it also contained sarcoma component somatic type malignancy. Metastases showed rhabdomyoblastic differentiation histologically identical diagnosed as rhabdomyosarcoma. By applying fluorescence in situ hybridization (FISH) cytogenetic examination...

10.1111/j.1600-0643.2007.00582.x article EN Apmis 2007-11-01

Laryngeal squamous cell carcinoma is a major medical problem worldwide. Although our understanding of genetic changes and their consequences in laryngeal cancer has opened new therapeutic pathways over the years, diagnostic as well treatment options still need to be improved. In previous study, we identified CRKL (22q11) novel putative oncogene overexpressed amplified subset LSCC tumors lines. Here analyze what extent DNA copy number gains correlate with higher expression protein by...

10.1038/s41598-019-56870-5 article EN cc-by Scientific Reports 2020-01-08

Objectives: Endometrial cancers (ECs) are the most common gynaecological in well developed countries. Diabetes and metabolic syndrome among biggest risk factors. Nesfatin-1, adipokine derivative of NUCB2 (nucleobindin 2) is linked to clinical course EC. Molecular factors, including mutations MLH1 MHS2 genes, c-MET ARID1A also related prognosis endometrial cancer. Material methods: Using sections paraffin-embedded preparations immunohistochemistry, expression NESF1, MLH1, MSH2,c-MET were...

10.5603/gp.2019.0099 article EN cc-by-nc-nd Ginekologia Polska 2019-10-31

Objective To evaluate the effect of supplementation dialysis fluid with N-acetylglucosamine (NAG) on permeability peritoneum during chronic peritoneal in rats. Design Experiments were performed rats surgically implanted catheters. Dialysis solution [DianeaI1.5% (Baxter, Deerfield, IL, U.S.A.) supplemented either NAG 50 mmol/L or glucose (control)] was infused intraperitoneally twice, every day, for 8 weeks. Peritoneal equilibration tests (PET) all animals at beginning study and after weeks...

10.1177/089686089801800212 article EN Peritoneal Dialysis International 1998-03-01

AbstractAim: To evaluate the method and results of sentinel node biopsy including immunohistochemical examinations in resectable colorectal cancer.Material methods: From April 2004 to 2005, was carried out with dye 27 patients operated on for cancer. The standard examination nodes consisted evaluation individual H&E-dyed specimens from bisection node. negative were examined use immunohistochemistry against cytokeratins AE1/AE3.Findings: identified 25 (92.6%). In a routine histopathological...

10.1080/00015458.2007.11680009 article EN Acta Chirurgica Belgica 2007-01-01

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Mackiewicz-Wysocka M, Czerwińska P, Filas V, et al. Oncogenic BRAF mutations and p16 expression in melanocytic nevi melanoma the Polish population. Advances Dermatology Allergology/Postępy Dermatologii i Alergologii. 2017;34(5):490-498. doi:10.5114/ada.2017.71119. APA Mackiewicz-Wysocka, M., Czerwińska, P., Filas, V., Bogajewska, E., Kubicka, A., & Przybyła, A. (2017). Alergologii, 34(5), 490-498....

10.5114/ada.2017.71119 article EN cc-by-nc-sa Advances in Dermatology and Allergology 2017-01-01
Coming Soon ...